A Multicenter,2-Arm,Randomized,Controlled Study Evaluate the Effectiveness of the UltraShape® Contour I VER 3.1 System for Non-Invasive Reduction in Abdominal Circumference

November 10, 2013 updated by: UltraShape

A Multicenter,Two-Arm,Randomized,Controlled Study for the Evaluation of the Treatment of Adipose Tissue Using a Focused Ultrasound Device

The primary objective of this study is to evaluate the effectiveness of the Contour I VER 3.1 System on abdominal midsection circumference reduction relative to no treatment.

The secondary objective of this study is to assess subject satisfaction measured with a self-assessment questionnaire

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

156

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Petah Tikva, Israel, 49100
        • Department of Plastic Surgery and Burns Rabin Medical Center - Beilinson Hospital
    • Louisiana
      • Metairie, Louisiana, United States, 70006
        • Dr. William Patrick Coleman, III
    • Maryland
      • Hunt Valley, Maryland, United States, 21030
        • MD Laser Skin & Vein Institute
    • New Jersey
      • Montclair, New Jersey, United States, 07042
        • New-Jersey Plastic Surgery
    • Texas
      • Dallas, Texas, United States, 75390-9132
        • Dr. Jeffrey Kenkel

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Female or male subjects, 18 and 65 years of age at the time of enrollment
  2. Abdominal fat thickness of at least 1.5 cm (measurement by caliper)
  3. For women of child-bearing potential:

    1. negative urine pregnancy test.
    2. Women of child bearing age are required to be using an acceptable form of birth control for the duration of the study.
  4. General good health confirmed by medical history and skin examination of the treated area
  5. Written informed consent to participate in the study
  6. Ability to comply with the requirements of the study
  7. BMI ≤ 30

    Intra-procedural Inclusion criteria (prior to starting the treatment phase):

    subjects are eligible to continue the study and participate in the treatment phase if she meets all of the following intra-procedural inclusion criteria:

  8. For women of child-bearing potential: negative pregnancy test
  9. Abdominal fat thickness of at least 1.5 cm prior to initial treatment (measurement by caliper)

Exclusion Criteria:

  1. History of hypertension, ischemic heart disease, valvular heart disease, congestive heart failure, pacemaker/defibrillator, abdominal aortic aneurysm
  2. Current hyperlipidemia, diabetes mellitus, hepatitis, liver disease, HIV positive status, blood coagulopathy or excessive bleeding, autoimmune or connective tissue disease or malignancy.
  3. Previous liposuction in the treatment area
  4. History of skin disease in the treatment area, known tendency to form keloids or poor wound healing
  5. Skin lesions in the treatment area other than simple nevi on physical examination (e.g., atypical nevus, tattoo, abrasions) including depressed scars in the treatment area
  6. Poor skin quality (i.e., laxity)
  7. Abdominal wall diastasis or hernia on physical examination
  8. Abnormal kidney, liver or coagulation functions, abnormal lipid profile or blood count within the last 3 months
  9. Obesity (BMI > 30)
  10. Childbirth within the last 12 months or breastfeeding women.
  11. Any acute or chronic condition which, in the opinion of the Investigator, could interfere with the conduct of the study
  12. Unstable weight within the last 6 months (i.e., ± 3% weight change in the prior six months)
  13. Inability to comply with circumference measurement procedure (e.g., inability to held breath for the required duration)
  14. Participation in another clinical study within the last six months.
  15. Previous body contouring treatments in the areas of the abdomen and flanks.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group 1 - Non Invasive Ultrasound
Group 1 3 visits - Measurement of abdominal circumferences 3 visits - Treatment with Ultrashape Contour I VER 3.1 4 visits - Follow up visits The intervention is non invasive ultrasound.
Each treatment session is estimated to take approximately 60 minutes and will be performed on a bi-weekly basis.
Experimental: Group 2 - Non Invasive Ultrasound
Group 2 3 visits - Treatment with Contour I VER 3.1 system 3 visits - Measurements of abdominal circumference 4 visits - Follow Up visits The intervention is non invasive ultrasound.
Each treatment session is estimated to take approximately 60 minutes and will be performed on a bi-weekly basis.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The primary objective of this study is to evaluate the effectiveness of the Contour I VER 3.1 System on abdominal midsection circumference reduction relative to no treatment
Time Frame: 5-6 months
Reduction in circumference measurement of the abdomen from baseline
5-6 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Assess subject satisfaction measured with a self-assessment questionnaire
Time Frame: 5-6 months
5-6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2012

Primary Completion (Actual)

October 1, 2013

Study Completion (Actual)

October 1, 2013

Study Registration Dates

First Submitted

October 17, 2011

First Submitted That Met QC Criteria

October 28, 2011

First Posted (Estimate)

October 31, 2011

Study Record Updates

Last Update Posted (Estimate)

November 13, 2013

Last Update Submitted That Met QC Criteria

November 10, 2013

Last Verified

November 1, 2013

More Information

Terms related to this study

Other Study ID Numbers

  • US-0711

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Body Sculpting

Clinical Trials on Non Invasive Ultrasound

Subscribe